Clinical recommendations for the diagnosis and treatment of aplastic anemia (2019 edition)
https://doi.org/10.35754/0234-5730-2020-65-2-208-226
Abstract
Introduction. At the initiative of the Russian Hematology Society, the research group for the study of idiopathic aplastic anemia has developed clinical recommendations for the diagnosis and treatment of idiopathic aplastic anemia.
Aim: to standardize diagnostic and therapeutic approaches for the treatment of acquired aplastic anemia in Russia.
Methods. The methodological approaches used are based on the principles of evidence-based medicine, based on the recommendations of the Russian council of experts on the diagnosis and treatment of patients with idiopathic aplastic anemia, Russian and international experience in managing patients, and the recommendations of the European group for the study of aplastic anemia.
Results. A new revised and updated version of the national clinical guidelines is presented.
Conclusion. These recommendations are intended for doctors of various specialties, health administrators, and medical school students.
Conflict of interest: the authors declare no conflict of interest.
Financial disclosure: this study did not have sponsorship.
About the Authors
E. A. MihailovaRussian Federation
Elena A. Mihailova, Dr. Sci. (Med.), Professor, Leading Researcher, Department of Chemotherapy of Hematological malignancies and Hematopoietic and Bone Marrow Transplantation
tel.: +7(495) 613-26-90
Z. T. Fidarova
Russian Federation
Zalina T. Fidarova, Cand. Sci. (Med.), Head of day hospital for Chemotherapy of Hematological malignancies and Hematopoietic Depressions
tel.: +7(495) 612-45-92.
V. V. Troitskaya
Russian Federation
Vera V. Troitskaya, Cand. Sci. (Med.), Head of the Intensive High-Dose Chemotherapy Department for patients with Hematological malignancies and Hematopoietic Depressions
tel.: +7(495) 612-45-92.
G. A. Klyasova
Russian Federation
Galina A. Klyasova, Dr. Sci. (Med.), Professor, Head of the Laboratory of Clinical Bacteriology, Mycology, and Antibiotic Therapy
A. D. Kulagin
Russian Federation
Alexander D. Kulagin, Dr. Sci. (Med.), Professor of the Department of Hematology, Transfusiology and Transplantation
tel.: +7 (812) 338-62-84
E. V. Voronova
Russian Federation
Elena V. Voronova, Head of the Department of Hematology
Chief Hematologist of the Tambov region
V. N. Dvirnyk
Russian Federation
Valentina N. Dvirnyk, Cand. Sci. (Med.), Head of the Centralized Clinical and Diagnostic Laboratory
I. V. Galtseva
Russian Federation
Irina V. Galtseva, Cand. Sci. (Med.), Head of Laboratory for Immunophenotyping of Blood and Bone Marrow Cells
A. M. Kovrigina
Russian Federation
Alla M. Kovrigina, Dr. Sci. (Biol.), Head of the Pathology Department
T. N. Obukhova
Russian Federation
Tatyana N. Obukhova, Cand. Sci. (Med.), Head of the Laboratory of Karyology
T. V. Gapanova
Russian Federation
Tatyana V. Gapanova, Cand. Sci. (Med.), Deputy Director for Transfusiology
E. N. Parovichnikova
Russian Federation
Elena N. Parovichnikova, Dr. Sci. (Med.), Head of the Department of Chemotherapy of Hematological malignancies and Hematopoietic Depressions and Bone Marrow Transplantation
V. G. Savchenko
Russian Federation
Valery G. Savchenko, Dr. Sci. (Med.), Professor, Chief Hematology Specialist of the Ministry of Health of the Russian Federation, RAS Academician, Head
References
1. Young N.S. Pathophysiologic mechanisms in acquired aplastic anemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2006: 72–7.
2. Zeng Y., Katsanis E. The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol. 2015; 180(3): 361–70. DOI: 10.1111/cei.12605.
3. Medinger M., Drexler B., Lengerke C., et al. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment. Front Oncol. 2018; 8: 1–10. DOI: 10.3389/fonc.2018.00587.
4. Isidori A., Borin L., Elli E., et al. Iron toxicity — Its effect on the bone marrow. Blood Rev. 2018; 32(6): 473–9. DOI: 10.1016/j.blre.2018.04.004.
5. Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options? Blood. 2013; 122(22): 3561–7. DOI: 10.1182/blood-2013-05-498279.
6. Frickhofen N., Heimpel H., Kaltwasser J.P., et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003; 101(4): 1236–42. DOI: 10.1182/blood-2002-04-1134.
7. Afable M.G., Tiu R. V, Maciejewski J.P. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011: 90–5. DOI: 10.1182/asheducation-2011.1.90.
8. Pu J.J., Mukhina G., Wang H., et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol. 2011; 87(1): 37–45. DOI: 10.1111/j.1600-0609.2011.01615.x.
9. Socié G., Mary J.-Y., de Gramont A., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996; 348(9027): 573–7. DOI: 10.1016/S0140-6736(95)12360-1.
10. Kulagin A., Lisukov I., Ivanova M., et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study. Br J Haematol. 2014; 164(4): 546–54. DOI: 10.1111/bjh.12661.
11. Li Y., Li X., Ge M., et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience. Ann Hematol. 2011; 90(5): 529– 37. DOI: 10.1007/s00277-010-1140-9.
12. Kulagin A.D., Lisukov I.A, Ptushkin V.V., Shilova E.R., Tsvetaeva N.V., Mikhailova E.A. National guidelines for the diagnosis and treatment of paroxismal nocturnal hemoglobinuria. Onkohematologiay. 2014; 2: 20–8 (In Russian).
13. Kaufman D.W., Kelly J.P., Issaragrisil S., et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol. 2006; 81: 65–67. DOI: 10.1002/ajh.20489.
14. Mikhailova E.A. Protocol of programm treatment for patients with aplastic anemia: combined immunosuppressive therapy. In: Savchenko V.G. Ed. Programmed treatment of diseases of the blood and bone marrow. Moscow: Practice; 2012: 135–50 (In Russian).
15. Killick S.B., Bown N., Cavenagh J., et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016; 172(2): 187–207. DOI: 10.1111/bjh.13853.
16. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program. 2011; 2011: 480–6. DOI: 10.1182/asheducation-2011.1.480.
17. Soulier J. Fanconi anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011: 492–7. DOI: 10.1182/asheducation-2011.1.492.
18. Marsh J.C.W., Ball S.E., Cavenagh J., et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147(1): 43–70. DOI: 10.1111/j.1365-2141.2009.07842.x.
19. Peslak S.A., Olson T., Babushok D. V. Diagnosis and Treatment of Aplastic Anemia. Vol. 18, Current Treatment Options in Oncology. Springer New York LLC; 2017. DOI: 10.1007/s11864-017-0511-z.
20. Barone A., Lucarelli A., Onofrillo D., et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells, Mol Dis. 2015; 55(1): 40–7. DOI: 10.1016/j.bcmd.2015.03.007.
21. Frisch B., Lewis S.M. The bone marrow in aplastic anaemia: diagnostic and prognostic features. J Clin Pathol. 1974; 27(3): 231–41. DOI: 10.1136/jcp.27.3.231.
22. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008; 112(4): 965–74. DOI: 10.1182/blood-2008-02-130435.
23. Maciejewski J.P., Risitano A., Sloand E.M., et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002; 99(9): 3129–35. DOI: 10.1182/blood.V99.9.3129.
24. Gupta V., Brooker C., Tooze J.A., et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. 2006; 134(1): 95–9. DOI: 10.1111/j.1365-2141.2006.06105.x.
25. Olshanskaya J.V., Mikhailova E.A., Domracheva E.V., et al. Clonal chromosomal rearrangements in patients with aplastic anemia at the onset of the disease and during transformation. Terapevticheskiy arkhiv 2006; 78: 31–7 (In Russian).
26. Dumitriu B., Feng X., Townsley D.M., et al. Red cells, iron, and erythropoiesis: Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood. 2015; 125(4): 706–9. DOI: 10.1182/blood-2014-10-607572.
27. Jerez A., Clemente M.J., Makishima H., et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122(14): 2453–9. DOI: 10.1182/blood-2013-04-494930.
28. Du Y., Long Z., Chen M., et al. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. Acta Haematol. 2017; 138(2): 119–28. DOI: 10.1159/000479422.
29. Borowitz M.J., Craig F.E., Digiuseppe J.A., et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by fl ow cytometry. Cytom Part B — Clin Cytom. 2010; 78(4): 211–30. DOI: 10.1002/cyto.b.20525.
30. Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood. 2016; 128(3): 337-47. DOI: 10.1182/blood-2016-01-636381.
31. Parker C.J. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Progr. 2016; 2016(1): 208–16. DOI: 10.1182/asheducation-2016.1.208.
32. Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program. 2007; 29–39. DOI: 10.1182/asheducation-2007.1.29.
33. Mikhailova E.A., Fidarova Z.T., Ustinova E.N., et al. Combined immunosuppressive therapy of aplastic anemia: repeated courses of horse antithymocytic globulin. Gematologiya i transfusiologiya 2014; 59: 11–8 (In Russian).
34. Young N.S., Bacigalupo A., Marsh J.C.W. Aplastic Anemia: Pathophysiology and Treatment. Biol Blood Marrow Transplant. 2010; 16(1): S119–25. DOI: 10.1016/j.bbmt.2009.09.013.
35. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017; 129(11): 1428–36. DOI: 10.1182/blood-2016-08-693481.
36. Scheinberg P., Young N.S. How I treat acquired aplastic anemia. Blood. 2012; 120(6): 1185–96. DOI: 10.1182/blood-2011-12-274019.
37. Desmond R., Townsley D.M., Dumitriu B., et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014; 123(12): 1818–25. DOI: 10.1182/blood-2013-10-534743.
38. Lee J.W., Yoon S.-S., Shen Z.X., et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial. Blood. 2010; 116(14): 2448–54. DOI: 10.1182/blood-2010-01-261289.
39. Kelsey P., Murphy M.F., Brown M., et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2003; 122(1): 10–23. DOI: 10.1046/j.1365-2141.2003.04468.x.
40. Bacigalupo A., Brand R., Oneto R., et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy — The European Group for blood and marrow transplantation experience. Semin Hematol. 2000; 37(1): 69–80.
41. Bacigalupo A., Würsch A., Hows J.M., et al. Long‐term follow‐up of severe aplastic anaemia patients treated with antithymocyte globulin. Br J Haematol. 1989; 73(1): 121–6. DOI: 10.1111/j.1365-2141.1989.tb00230.x.
42. Rosenfeld S., Follmann D., Nunez O., et al. Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia: Association between Hematologic Response and Long-term Outcome. J Am Med Assoc. 2003; 289(9): 1130–5. DOI: 10.1001/jama.289.9.1130.
43. Marchiò C., Dowsett M., Reis-Filho J.S. Revisiting the technical validation of tumour biomarker assays: How to open a Pandora’s box. BMC Med. 2011; 9. DOI: 10.1186/1741-7015-9-41.
44. Bacigalupo A., Hows J., Gluckman E., et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party. Br J Haematol. 1988; 70(2): 177–82.
45. Scheinberg P., Townsley D., Dumitriu B., et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol. 2014; 89(5): 467–9. DOI: 10.1002/ajh.23669.
46. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program. 2012; 2012: 292–300. DOI: 10.1182/asheducation-2012.1.292.
47. Miano M., Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015; 101(6): 527–35. DOI: 10.1007/s12185-015-1787-z.
48. Peffault de Latour R., Tabrizi R., Marcais A., et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol. 2018; 93(5): 635–42. DOI: 10.1002/ajh.25050.
49. Valdez J.M.J.M., Scheinberg P., Nunez O., et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011; 52(6): 726–35. DOI: 10.1093/cid/ciq245.
50. Winkler T., Fan X., Cooper J., et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019; 133(24): 2575–85. DOI: 10.1182/blood.2019000478.
51. Olnes M.J., Scheinberg P., Calvo K.R., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1): 11–9. DOI: 10.1056/NEJMoa1200931.
52. Desmond R., Townsley D.M., Dunbar C., et al. Eltrombopag in Aplastic Anemia. Seminars in Hematology. 2015. DOI: 10.1053/j.seminhematol.2014.10.002.
Review
For citations:
Mihailova E.A., Fidarova Z.T., Troitskaya V.V., Klyasova G.A., Kulagin A.D., Voronova E.V., Dvirnyk V.N., Galtseva I.V., Kovrigina A.M., Obukhova T.N., Gapanova T.V., Parovichnikova E.N., Savchenko V.G. Clinical recommendations for the diagnosis and treatment of aplastic anemia (2019 edition). Russian journal of hematology and transfusiology. 2020;65(2):208-226. (In Russ.) https://doi.org/10.35754/0234-5730-2020-65-2-208-226